Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets. The company was founded by two remarkable scientists PhD Jan Tkac and PhD Tomas Bertok who got international recognition for their scientific works, prestigious grants and awards winners such as Scientists of the year (Slovakia), European Research Council (ERC) Consolidator grant, Marie Skłodowska-Curie actions ITN, Qatar National Research Fund.
The mission of the project is to develop glycan-based reliable, accurate, quantitative, affordable and less-invasive tests for cancer diagnostics which could save thousands of patients from misdiagnosis in early stages of the disease. The Report on the implementation of the Council Recommendation on cancer screening concludes that nearly 50% of cancer deaths can be avoided. Glycanostics first product – Prostate Cancer DX kit - can provide a reliable and precise early cancer diagnosis, avoiding unnecessary biopsies and potentially aggressive treatment.
“Based on “glycocode deciphering“ our test is done by the analysis of glycan changes on specific proteins like PSA directly in human serum. Being much more precise than currently existing methods our innovative approach is designed to help doctors to make a proper decision about the correct need to perform a biopsy or a re-biopsy,”
comment PhD Jan Tkac and PhD Tomas Bertok, founders of Glycanostics Ltd.
The company plans to introduce the first product – Prostate Cancer DX kit - already in 2019 as a second opinion test helpful to currently existing but less precise PSA and biopsy tests.
This project received the highest scores for its proposal in the extremely competitive evaluation process.
Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.
Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.
In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.